|

RiMO-301 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Coordination Pharmaceuticals, Inc.1

Indications

  • Head Neck Cancer1
  • Intratumoral Injection1
  • Cancer1

Chicago, Illinois1 trial

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

University of Illinois at Chicago

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.